NEW DELHI: The development of childhood wheezing illnesses has long been linked to severe respiratory syncytial virus RSV infection, but the connection between RSV infection during infancy and the emergence of childhood asthma has remained unclear. The findings of the study was published in the journal The Lancet. Researchers at Vanderbilt University Medical Centre have discovered a new observational study that links RSV infection in the first year of life to a markedly higher risk of asthma in children. The study, which is the first to examine how RSV infections of various severity levels affect the incidence of paediatric asthma at the community level. RSV is a seasonal respiratory virus that affects almost all children by the age of 2 and repeatedly throughout life. It is the leading cause of bronchiolitis, a lower respiratory tract infection that presents as coughing and wheezing in infants and young children. The symptoms are mild in most children and usually resolve in about a week, but it can lead to serious illness and death especially in premature or very young infants and those with chronic lung disease or congenital heart disease. It is the most common cause of hospitalizations worldwide due to respiratory issues in the first year of life, said Christian Rosas Salazar, MD, MPH, assistant professor of Pediatrics in the Division of Allergy, Immunology and Pulmonary Medicine, the first author of the study.
For 60 years investigators have repeatedly identified the link between severe RSV and asthma; however, we ve shown that this link is explained in part by shared heredity to both severe RSV and asthma, said the study s principal investigator and senior author Tina Hartert, MD, MPH, professor of Medicine and Pediatrics, director of the Center for Asthma and Environmental Sciences Research, Vice President for Translational Research and the Lulu H. Owen Professor of Medicine. The solution in our study was to understand the link between RSV and asthma by ensuring all RSV infections would be captured using molecular techniques and post season serology, she said. In our study, among healthy children born at term, not being infected with RSV in the first year of life was associated with a substantially reduced risk of developing childhood asthma, which affects about 8 of the children in the U.S., Rosas Salazar said. Our findings show an age dependent association between RSV infection during infancy and childhood asthma. We focused on the first year of life because we think the first year is a very important period of lung and immune development, Rosas Salazar said.
We believe that when a child is infected with RSV in the first year of life, when the lungs and immune system are still under development, that could lead to certain abnormalities that can later cause asthma, he said. The INSPIRE Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure study included 1,946 eligible healthy infants who were 6 months old or younger at the beginning of RSV season November to March in Tennessee . The infants were recruited from 11 pediatric practices across Middle Tennessee. Biweekly surveillance and serology tests were used to classify infants as infected or not infected in the first year of life. Fifty four percent of infants were infected with RSV in the first year of life; 46 were uninfected. RSV is a seasonal respiratory virus that affects almost all children by the age of 2 and repeatedly throughout life. It is the leading cause of bronchiolitis, a lower respiratory tract infection that presents as coughing and wheezing in infants and young children. The symptoms are mild in most children and usually resolve in about a week, but it can lead to serious illness and death especially in premature or very young infants and those with chronic lung disease or congenital heart disease.
The infants were followed annually and then evaluated for asthma at 5 years old. The study found infants who weren t infected with RSV in the first year of life had a 26 lower risk of asthma at age 5. The symptoms are mild in most children and usually resolve in about a week, but it can lead to serious illness and death especially in premature or very young infants and those with chronic lung disease or congenital heart disease. We hope the results of this study motivate long term follow up of common respiratory outcomes among children in ongoing clinical trials of RSV prevention products, including vaccines and monoclonal antibodies that can decrease the severity of the infection, Rosas Salazar said. Showing efficacy of RSV vaccines against childhood asthma would increase public health interest and vaccine uptake, Hartert said.
